Coeptis
-
Coeptis Therapeutics’ Dave Mehalick on Making Cell Therapy Universally Accessible
April 30, 2024 — In a recent interview with InvestorNews, Dave Mehalick, Chairman, President, and CEO of Coeptis…
-
Dave Mehalick from Coeptis Therapeutics to Host InvestorTalk (04.25.2024)
InvestorNews is pleased to announce an upcoming InvestorTalk scheduled for Thursday, April 25th at 9 AM EST, featuring…
-
Coeptis Therapeutics’ Dave Mehalick on the disruptive potential of SNAP-CAR technology for autoimmune diseases
In an insightful interview with Tracy Weslosky, Dave Mehalick, Chairman, President, and CEO of Coeptis Therapeutics Holdings, Inc.…
-
Dr. Colleen Delaney from Coeptis Therapeutics on the development of next-generation cell therapy technologies for cancer and infectious diseases
In a recent Investor.Coffee interview with host Jack Lifton, Dr. Colleen Delaney, Chief Scientific and Medical Officer at…
-
Coeptis CEO Dave Mehalick on NASDAQ listing and entering the Cancer Treatment Race
Innovative cell therapy platforms have the potential to disrupt conventional cancer treatment In an InvestorCoffee interview with host…
